Mode
Text Size
Log in / Sign up

Allergic Bronchopulmonary Aspergillosis

Part of Hypersensitivity, Immediate

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Allergic Bronchopulmonary Aspergillosis

5 trials tracked for Allergic Bronchopulmonary Aspergillosis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 227 citations.

5Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 1 Phase 1 1 Other / NA 1
  1. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Completed · 227 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Completed
  3. Phase 2 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Completed
  4. Phase 1 Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Completed
  5. N/A Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hypersensitivity, Immediate

Related studies from across the Hypersensitivity, Immediate family.

Astragali Radix metabolites show anti-inflammatory and immunomodulatory activities for allergic respiratory conditions
Drug Pipeline Sys. Review
Astragali Radix metabolites show anti-inflammatory and immunomodulatory activities for allergic respiratory conditions Astragali Radix metabolites show promise for allergic airway diseases
This narrative review examines the potential of Astragali Radix metabolites, including polysaccharides, saponins, and flavonoids, for allerg…
A review suggests Astragali Radix metabolites may help treat allergic asthma and related conditions through anti-inflammatory and immunomodu…
Narrative review identifies emerging associations between gut microbiota and pediatric eye conditions
Ophthalmology Sys. Review
Narrative review identifies emerging associations between gut microbiota and pediatric eye conditions Early gut bugs may shape your child's eye health for life
This narrative review examines associations between gut microbiota dysbiosis and pediatric ophthalmic conditions including myopia and allerg…
New research suggests that the tiny bugs living in a child's gut could be the hidden reason behind their eye problems.
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery
Allergy & Immunology FDA Approval
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery FDA approves Dupixent for treating allergic fungal sinus infections in patients who have had sinus surgery
Dupixent (dupilumab) has been approved for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosi…
FDA approves Dupixent for allergic fungal sinus infections in adults and children aged 6 and older who have had sinus surgery.